Discovery of a Selective Covalent Inhibitor of Lysophospholipase-like 1 (LYPLAL1) as a Tool to Evaluate the Role of this Serine Hydrolase in Metabolism
Citations Over TimeTop 11% of 2016 papers
Abstract
Lysophospholipase-like 1 (LYPLAL1) is an uncharacterized metabolic serine hydrolase. Human genome-wide association studies link variants of the gene encoding this enzyme to fat distribution, waist-to-hip ratio, and nonalcoholic fatty liver disease. We describe the discovery of potent and selective covalent small-molecule inhibitors of LYPLAL1 and their use to investigate its role in hepatic metabolism. In hepatocytes, selective inhibition of LYPLAL1 increased glucose production supporting the inference that LYPLAL1 is a significant actor in hepatic metabolism. The results provide an example of how a selective chemical tool can contribute to evaluating a hypothetical target for therapeutic intervention, even in the absence of complete biochemical characterization.
Related Papers
- → Crystal structure of yeast YHR049W/FSH1, a member of the serine hydrolase family(2005)21 cited
- → Measuring the Global Substrate Specificity of Mycobacterial Serine Hydrolases Using a Library of Fluorogenic Ester Substrates(2018)16 cited
- → Tuberculosis serine hydrolase variable expression, isolation, and characterization under hypoxia conditions(2018)
- → Global substrate specificity of mycobacterial serine hydrolases(2017)
- → Transition Metal Cation Inhibition of Mycobacterium tuberculosis Esterase Rv0045c(2016)